Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 16Neoplasms 6Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1HER2+ Metastatic Breast Cancer (MBC) 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

NCT01953926 2024-03-12

SUMMIT

Puma Biotechnology, Inc.

Phase 2 Terminated
582 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00266877 2018-04-13

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
172 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡